全文获取类型
收费全文 | 588篇 |
免费 | 26篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 50篇 |
妇产科学 | 11篇 |
基础医学 | 53篇 |
口腔科学 | 12篇 |
临床医学 | 35篇 |
内科学 | 102篇 |
皮肤病学 | 9篇 |
神经病学 | 16篇 |
特种医学 | 136篇 |
外科学 | 36篇 |
综合类 | 5篇 |
预防医学 | 82篇 |
眼科学 | 23篇 |
药学 | 25篇 |
肿瘤学 | 28篇 |
出版年
2022年 | 4篇 |
2021年 | 5篇 |
2019年 | 4篇 |
2018年 | 7篇 |
2017年 | 6篇 |
2016年 | 5篇 |
2015年 | 22篇 |
2014年 | 12篇 |
2013年 | 25篇 |
2012年 | 33篇 |
2011年 | 14篇 |
2010年 | 19篇 |
2009年 | 13篇 |
2008年 | 22篇 |
2007年 | 21篇 |
2006年 | 22篇 |
2005年 | 21篇 |
2004年 | 9篇 |
2003年 | 22篇 |
2002年 | 18篇 |
2001年 | 10篇 |
2000年 | 30篇 |
1999年 | 16篇 |
1998年 | 31篇 |
1997年 | 46篇 |
1996年 | 35篇 |
1995年 | 21篇 |
1994年 | 20篇 |
1993年 | 6篇 |
1992年 | 7篇 |
1991年 | 3篇 |
1990年 | 7篇 |
1989年 | 11篇 |
1988年 | 11篇 |
1986年 | 7篇 |
1985年 | 5篇 |
1984年 | 2篇 |
1983年 | 11篇 |
1982年 | 5篇 |
1981年 | 4篇 |
1980年 | 5篇 |
1978年 | 4篇 |
1977年 | 7篇 |
1976年 | 4篇 |
1975年 | 3篇 |
1974年 | 2篇 |
1968年 | 2篇 |
1966年 | 1篇 |
1959年 | 1篇 |
1958年 | 1篇 |
排序方式: 共有627条查询结果,搜索用时 15 毫秒
101.
102.
T. Braun Z. Chaloupka J. Neuwirf 《Naunyn-Schmiedeberg's archives of pharmacology》1958,233(3):226-232
Zusammenfassung 1. Chlorpromazin in täglichen Dosen von 2 mg/kg Gewicht verringert die Retention von Stickstoff im Organismus.2. Chlorpromazin in größeren Dosen führt bei Kaninchen zu erhöhter Ausscheidung von stickstoffhaltigen Stoffen, zur negativen Stickstoffbilanz und zum Absinken des Körpergewichtes.3. Auf Grund unserer Ergebnisse und der Feststellungen anderer Autoren nehmen wir an, daß chlorpromazin die Desaminierungsvorgänge in der Leber und in den Nieren beeinflußt.Mit 2 Textabbildungen 相似文献
103.
104.
105.
Background
Hemolytic uremic syndrome (HUS) leading to acute kidney failure, is a condition linked to the production of primarily Shiga toxin 2 (Stx2) by some E. coli serotypes. We have previously shown that Stx2 A subunit-specific human monoclonal antibody (HuMAb) 5C12, and B subunit-specific HuMAb 5H8 inhibit cultured cell death, and protect mice and piglets from fatal Stx2-intoxication. We have also shown that 5H8 blocks binding of Stx2 to its cell-surface receptor globotriaosyl ceramide (Gb3), whereas Stx2 when complexed with 5C12 binds Gb3 with higher affinity than Stx2. The mechanism by which 5C12 neutralizes Stx2 in vitro involves trapping of Stx2 in the recycling endosomes and releasing it into the extracellular environment. Because of the clinical implications associated with the formation of Stx2/antibody complexes and the potential for trapping and clearance through a severely damaged kidney associated with HUS, we investigated the likely site(s) of Stx2/antibody localization and clearance in intoxicated mice treated with antibody or placebo.Results
Mice were injected with radiolabeled Stx2 (125I-Stx2) 4 hours after administration of 5C12, 5H8, or phosphate buffered saline (PBS) and the sites of localization of labeled Stx2, were investigated 3, 24 and 48 hours later. The liver recorded statistically much higher concentrations of labeled Stx2 for groups receiving 5C12 and 5H8 antibodies after 3, 24 and 48?hours, as compared with the PBS group. In contrast, highest levels of labeled Stx2 were detected in the kidneys of the PBS group at all 3 sampling times. Mice receiving either of the two HuMAbs were fully protected against the lethal effect of Stx2, as compared with the fatal outcome of the control group.Conclusions
The results suggest that HuMAbs 5C12 and 5H8 promoted hepatic accumulation and presumably clearance of toxin/antibody complexes, significantly diverting Stx2 localization in the kidneys, the target of Stx2 and the cause of HUS. This is in contrast to the fatal outcome of the control group receiving PBS. The results also confirm earlier observations that both HuMAbs are highly and equally protective against Stx2 intoxication in mice. 相似文献106.
107.
The relationship between alcohol taxes and binge drinking: evaluating new tax measures incorporating multiple tax and beverage types 下载免费PDF全文
108.
Objective
To examine and compare the extent to which people with type 2 diabetes (T2DM) are achieving haemoglobin A1c (HbA1c), blood pressure (BP) and LDL cholesterol (LDL-C) treatment targets.Methods
A review of databases (MEDLINE Ovid, Pubmed and Sabinet) was performed and limited to the following terms: type 2 diabetes mellitus AND guideline AND goal achievement for the years 2009 to 2014 (five years).Results
A total of 14 studies (25 629 patients) were selected across 19 different countries. An HbA1c level of 7.0% (or less) was achieved by 44.5% of subjects (range 19.2–70.5%), while 35.2% (range 7.4–66.3%) achieved BP of 130/80 mmHg (or less), and 51.4% (range 20.0–82.9%) had an LDL-C level of either 2.5 or 2.6 mmol/l (100 mg/dl or less).Conclusion
Despite guideline recommendations that lowering of HbA1c, BP and lipids to target levels in T2DM will lead to a reduction in morbidity and mortality rates, we found that control of these risk factors remains suboptimal, even across different settings. 相似文献109.
观察三维超声心动图测定机械瓣瓣口面积的可行性。方法11例机械瓣置换病例,用任意 切面(anyplane)3DE测定机械瓣瓣口有效面积,将测定值与多普勒超声心动图(DE)测定的有效瓣口面积(包括实测值和文献报道测值)及生产厂商提供的离体瓣口面积比较。 相似文献
110.
The authors developed quantitative radioimmunoassays to allow direct measurement of total human IgG and individual IgG subclasses among antibodies bound to cell surfaces. The assays use four mouse monoclonal radioiodinated antibodies, one that reacts equally well with all four human IgG subclasses and three that are specific for human IgG subclasses 1, 2, or 3. The assays were used to analyze IgG subclass composition in 21 high-titer anti-D samples from Rh-negative volunteers immunized for Rh immunoglobulin production. Anti-D activity was restricted primarily to the IgG1 and IgG3 subclasses. Eleven of 21 sera demonstrated red cell antibodies with a marked predominance of IgG1 (87 +/- 3.6% of total IgG antibody, +/- SEM) and low levels of IgG3 (1.4 +/- 0.73%). In the remaining 10 sera, IgG3 made up a greater proportion of total IgG antibody (32 +/- 3.8%), although IgG1 was still predominant (61 +/- 4.1%). This observed dichotomy in the IgG subclass profiles of different anti-D sera may be a consideration in the selection of anti-D sera for the production of the immunoglobulin used in the prophylaxis of Rh-incompatible pregnancies. 相似文献